Impact That Matters

Learn about HNF’s Research Initiatives

Research programs that can change people’s lives

We prioritize research programs that will change people’s lives by partnering with innovative researchers and industry leaders.

We ONLY support projects that have potential to have an impact on human health.

 

TRIAD

HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) as a patient-led collaborative network with academia, government, and industry to develop treatments for CMT. Currently TRIAD involves many groups that span the drug discovery, drug development, and diagnostics continuum.

Our core philosophy mandates that we collaborate with our patient community and strategic partners compassionately, honestly and with integrity. The patient always comes first and drives our patient support and research efforts.

More on TRIAD

CMT & Pediatrics

HNF has a dedicated CMT & Pediatric initiative to support the development of clinical trials.  

More info

GRIN

As part of TRIAD, in 2013, the Global Registry for Inherited Neuropathies (GRIN) was developed as an extension to conduct patient-focused research & development for treatments and cures. The patient voice is at the forefront of all we do. By Incorporating the patient voice from the very beginning, our research programs have the greatest potential for success.

HNF funds research with one goal in mind, advancing to clinical trials. Partnerships vary depending on research goals, milestones met, preclinical or clinical development and the strategic alliance agreement. 

More on GRIN

Learn more on this topic

Latest News and Related Blog Posts

Cambridge-led natural history study identifies MTRFR/C12orf65 deficiency to improve diagnosis and therapy development

Cambridge-led natural history study identifies MTRFR/C12orf65 deficiency to improve diagnosis and therapy development

by | Apr 17, 2023 | , , , | 0 Comments

This research will potentially show a method that may be quicker and better at identifying baseline disease phenotypes to support research and clinical trials. Cambridge-led retrospective natural history study funded by the Hereditary Neuropathy Foundation identifies...

HNF is Reshaping Drug Repurposing for CMT

HNF is Reshaping Drug Repurposing for CMT

by | Mar 6, 2023 | , , , , , | 0 Comments

HNF has partnered with Rarebase, a public benefit precision medicine company that has screened a large library of FDA approved small molecules to identify candidates for various types of CMT. Their tech-enabled drug discovery platform is called Function™. There are many published discoveries on the genetic cause of many types of CMT, including an understanding of the basic mechanism of disease and potential targets for FDA-approved drug repurposing. It is this understanding that allows HNF and Rarebase to target the genetic root cause of CMT.